Factors Influencing the Treatment Response of Pigment Epithelium Detachment in Age-Related Macular Degeneration

American Journal of Ophthalmology

Volumn 160, Issue 4, 2015, Pages 732-738.e2

  Dirani, Ali ^a,b   Ambresin, Aude ^a,b   Marchionno, Laetitia ^a,b   Decugis, Doris ^a,b   Mantel, Irmela ^a,b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b Jules Gonin Eye Hospital Fondation Asile des Aveugles (Foundation Asylum for the Blind)   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CASE STUDY; CENTRAL RETINAL THICKNESS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETINA DETACHMENT; RETROSPECTIVE STUDY; SUBRETINAL FLUID; TREATMENT RESPONSE; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; INTRAVITREAL DRUG ADMINISTRATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PIGMENT EPITHELIUM; RETINAL DETACHMENT; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINAL DETACHMENT; RETINAL PIGMENT EPITHELIUM; RETROSPECTIVE STUDIES; SUBRETINAL FLUID; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84941413689     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2015.06.025     Document Type: Article

References (36)

1. D.M. Brown, P.K. Kaiser, M. Michels, and et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 14 2006 1432 1444
2. P.J. Rosenfeld, D.M. Brown, J.S. Heier, and et al. Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 14 2006 1419 1431
3. J.S. Heier, D.M. Brown, V. Chong, and et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration Ophthalmology 119 12 2012 2537 2548
4. U. Schmidt-Erfurth, P.K. Kaiser, J.-F. Korobelnik, and et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies Ophthalmology 121 1 2014 193 201
5. N. Papadopoulos, J. Martin, Q. Ruan, and et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab Angiogenesis 15 2 2012 171 185
6. W.Y. Shen, M.J. Yu, C.J. Barry, I.J. Constable, and P.E. Rakoczy Expression of cell adhesion molecules and vascular endothelial growth factor in experimental choroidal neovascularisation in the rat Br J Ophthalmol 82 9 1998 1063 1071
7. T. Tobe, N. Okamoto, M.A. Vinores, and et al. Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors Invest Ophthalmol Vis Sci 39 1 1998 180 188
8. N. Kwak, N. Okamoto, J.M. Wood, and P.A. Campochiaro VEGF is major stimulator in model of choroidal neovascularization Invest Ophthalmol Vis Sci 41 10 2000 3158 3164
9. M.G. Krzystolik, M.A. Afshari, A.P. Adamis, and et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment Arch Ophthalmol 120 3 2002 338 346
10. J.-M. Rakic, V. Lambert, L. Devy, and et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization Invest Ophthalmol Vis Sci 44 7 2003 3186 3193
11. I. Kim, A.M. Ryan, R. Rohan, and et al. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes Invest Ophthalmol Vis Sci 40 9 1999 2115 2121
12. D.S. McLeod, M. Taomoto, J. Cao, Z. Zhu, L. Witte, and G.A. Lutty Localization of VEGF receptor-2 (KDR/Flk-1) and effects of blocking it in oxygen-induced retinopathy Invest Ophthalmol Vis Sci 43 2 2002 474 482
13. N. Kumar, M. Marsiglia, S. Mrejen, and et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration Retina 33 8 2013 1605 1612
14. K.H. Patel, C.C. Chow, R. Rathod, and et al. Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab Eye 27 5 2013 663 667
15. M.W. Stewart, and P.J. Rosenfeld Predicted biological activity of intravitreal VEGF Trap Br J Ophthalmol 92 5 2008 667 668
16. M.J. Bottomley, N.J. Webb, C.J. Watson, and et al. Placenta growth factor (PlGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid Clin Exp Immunol 119 1 2000 182 188
17. B. Bakall, J.C. Folk, H.C. Boldt, and et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab Am J Ophthalmol 156 1 2013 15 22.e1
18. H. Cho, C.P. Shah, M. Weber, and J.S. Heier Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab Br J Ophthalmol 97 8 2013 1032 1035
19. V.Y. Ho, S. Yeh, T.W. Olsen, and et al. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors Am J Ophthalmol 156 1 2013 23 28
20. Y. Yonekawa, C. Andreoli, J.B. Miller, and et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration Am J Ophthalmol 156 1 2013 29 35
21. D.S. Grewal, M.K. Gill, D. Sarezky, A.T. Lyon, and R.G. Mirza Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results Eye 28 7 2014 895 899
22. F.M. Heussen, Q. Shao, Y. Ouyang, A.M. Joussen, and B. Müller Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration Graefes Arch Clin Exp Ophthalmol 252 6 2014 909 915
23. C.C. Wykoff, D.M. Brown, M.E. Maldonado, and D.E. Croft Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial) Br J Ophthalmol 98 7 2014 951 955
24. M. Gharbiya, L. Iannetti, F. Parisi, U. De Vico, M.L. Mungo, and M. Marenco Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration Bio Med Res Int 2014 2014 273754
25. A.A. Chang, H. Li, G.K. Broadhead, and et al. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration Ophthalmology 121 1 2014 188 192
26. A. Wolf, J. Rüping, A.S. Neubauer, and et al. Alterations of vascular pigment epithelium detachments associated with age-related macular degeneration during upload with intravitreal ranibizumab Retina 33 9 2013 1843 1849
27. O.S. Punjabi, J. Huang, L. Rodriguez, A.T. Lyon, L.M. Jampol, and R.G. Mirza Imaging characteristics of neovascular pigment epithelial detachments and their response to anti-vascular endothelial growth factor therapy Br J Ophthalmol 97 8 2013 1024 1031
28. D. Pauleikhoff, D. Löffert, G. Spital, and et al. Pigment epithelial detachment in the elderly. Clinical differentiation, natural course and pathogenetic implications Graefes Arch Clin Exp Ophthalmol 240 7 2002 533 538
29. A. Mariani, A. Deli, A. Ambresin, and I. Mantel Characteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age-related macular degeneration Graefes Arch Clin Exp Ophthalmol 249 11 2011 1635 1642
30. M. Bolz, S. Michels, W. Geitzenauer, F. Prager, and U. Schmidt-Erfurth Effect of systemic bevacizumab therapy on retinal pigment epithelial detachment Br J Ophthalmol 91 6 2007 785 789
31. T. Baba, M. Kitahashi, M. Kubota-Taniai, T. Oshitari, and S. Yamamoto Two-year course of subfoveal pigment epithelial detachment in eyes with age-related macular degeneration and visual acuity better than 20/40 Ophthalmol J Int Ophtalmol 228 2 2012 102 109
32. S. Julien, A. Biesemeier, T. Taubitz, and U. Schraermeyer Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes Br J Ophthalmol 98 6 2014 813 825
33. D. Malik, M. Tarek, J. Caceres del Carpio, and et al. Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture Br J Ophthalmol 98 Suppl 1 2014 i11 i16
34. U. Introini, A. Torres Gimeno, F. Scotti, M. Setaccioli, S. Giatsidis, and F. Bandello Vascularized retinal pigment epithelial detachment in age-related macular degeneration: treatment and RPE tear incidence Graefes Arch Clin Exp Ophthalmol 250 9 2012 1283 1292
35. M. Suzuki, N. Nagai, K. Izumi-Nagai, and et al. Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration Br J Ophthalmol 98 9 2014 1186 1191
36. G.J. Jaffe, D.F. Martin, C.A. Toth, and et al. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials Ophthalmology 120 9 2013 1860 1870